Phys Vivas · rheumatological
Eosinophilic Disorders — Viva Defence
DCE viva defence for Eosinophilic Disorders.
On this page
Study tools
Target exams
Eosinophilic Disorders Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Eosinophilic Disorders. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
References3ShowHide
- [1]Shomali W, Gotlib J World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management Am J Hematol, 2024.PMID 38551368
- [2]Klion AD Approach to the patient with suspected hypereosinophilic syndrome Hematology Am Soc Hematol Educ Program, 2022.PMID 36485140
- [3]Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis N Engl J Med, 2017.PMID 28514601